Share >  
Share
Share on Tumblr

Md And Ceo Glenn Saldanha

News »

   latest by relevance
Launches in FY13 to boost growth in Indian market: Glenmark
May 09, 2012 at 11:42 | Source: CNBC-TV18
Aided by malarone and cutivate generic, the US business of Glenmark Pharma saw recovery in the fourth quarter of FY12. In an interview with CNBC-TV18, Glenn Saldanha, MD & CEO of Glenmark said, the company expects its domestic market to outperform industry in FY13.
Building the India advantage amid global competitiveness
Sep 17, 2010 at 16:49 | Source: CNBC-TV18
In an interview on CNBC-TV18, an esteemed panel which included Glenn Saldanha, CEO & MD, Glenmark Pharmaceuticals Ltd, Partha S Bhattacharyya, Chairman, Coal India Ltd, R Gopalkrishnan, Executive Director, Tata Sons, Tarun Khanna, Professor, Harvard Business School, discussed competitiveness in business.
Tarka sales to rake in $ 5-7 m per quarter: Glenmark Pharma
Sep 15, 2010 at 11:20 | Source: CNBC-TV18
Glenn Saldanha MD and CEO of Glennmark Pharma said that he expects the sale of Tarka to rake in around USD 5- 7 million per quarter.
Glenmark Pharma expects to maintain EBIDTA margin ahead
May 28, 2010 at 17:00 | Source: CNBC-TV18
In an interview with CNBC-TV18, Glenn Saldanha, MD and CEO, Glenmark Pharma, speaks about the results and his outlook for the company.
FDA to take 10 months to approve Oxycodone: Glenmark
Mar 31, 2010 at 10:34 | Source: CNBC-TV18
Glenmark Generics had announced NDA for its drug Oxycodone Capsules. Speaking about it, Glenn Saldanha, MD & CEO, Glenmark told CNBC-TV18 that that US FDA should take 10 months to approve Oxycodone.
Growth prescription: Glenn Saldanha on Glenmark in 2010
Jan 19, 2010 at 19:37 | Source: CNBC-TV18
The recent ruling by the Federal Trade Commission may impact the generics industry. So says Glenn Saldanha, MD and CEO of Glenmark. In an interview with CNBC-TV18, Saldanha spoke about the recent FTC ruling, revenue kickers and out-licensing deals in 2010.

Videos »
Launches in FY13 to boost growth in Indian market: Glenmark
Building the India advantage amid global competitiveness
Tarka sales to rake in $ 5-7 m per quarter: Glenmark Pharma
Glenmark Pharma expects to maintain EBIDTA margin ahead
FDA to take 10 months to approve Oxycodone: Glenmark
more »

Photos »

  /  
Related News »
Launches in FY13 to boost growth in Indian market: Glenmark
In an interview with CNBC-TV18, Glenn Saldanha, MD & CEO of Glenmark said, the company expects its domestic market to outperform industry in FY13. Saldanha is positive about licensing income in FY13. Without the impact of forex, Glenmark ...
May 9, 2012 at 06:50 | Source: MoneyControl.com

Follow moneycontrol.com

Facebook Twitter Google Plus RSS Wap SMS SMS Alert iPad iPhone Blackberry OVI Android Window